Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04809740 · ClinicalTrials.gov registry record · NA
Evaluating the Implementation and Impact of Navigator-delivered ePRO System
A NA study of Cancer, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- NA
- Development phase
- 7,500
- Enrollment target
- 2
- Study locations
NCT04809740: Recruiting NA study of Cancer, sponsored by University of Alabama at Birmingham.
NCT04809740 is a NA study of Cancer that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 7,500 participants, above the 3,479-participant average among 615 other Cancer trials with a reported enrollment target (116% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04809740, a NA study of Cancer, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- NA
- Development phase
- 7,500 participants
- Enrollment target
- 2
- Study locations
Study Summary
1\) Evaluate implementation of navigator-delivered Home ePRO for all cancer patients across multiple practice sites; 2) examine the barriers, facilitators, and implementation strategies used in implementing navigator-delivered Home ePRO; and 3) assess the impact of Home ePRO on clinical and utilization outcomes.
Primary Outcome
% of eligible patients enrolled
Conditions Studied
Interventions
- OTHER Evaluate implementation of navigator-delivered Home ePRO for all cancer patients
Study Locations (2)
Alabama
- University of Alabama at Birmingham - Birmingham
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,500 participants |
| Start Date | 2021-05-04 |
| Est. Completion | 2027-01 |
| Phase | NA |
What NCT04809740 shows while recruiting
NCT04809740 is an interventional study that assigns participants to a tested intervention. Its 7,500 participants enrollment target places it among the larger protocols in the corpus, above the 3,479-participant average among 615 other Cancer trials with a reported enrollment target (116% higher).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Evaluate implementation of navigator-delivered Home ePRO for all cancer patients is the first listed.
NCT04809740 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT04809740 about?
NCT04809740 is a clinical study titled "Evaluating the Implementation and Impact of Navigator-delivered ePRO System". 1\) Evaluate implementation of navigator-delivered Home ePRO for all cancer patients across multiple practice sites; 2) examine the barriers, facilitators, and implementation strategies used in implementing navigator-delivered Home ePRO; and 3) assess the impact of Home ePRO on clinical and utilizat...
What is the current status of trial NCT04809740?
This trial is currently recruiting. It is a NA study. The enrollment target is 7,500 participants. The study started on 2021-05-04. Estimated completion is 2027-01.
What conditions does trial NCT04809740 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT04809740?
The interventions under investigation include: Evaluate implementation of navigator-delivered Home ePRO for all cancer patients (OTHER).
Who is sponsoring clinical trial NCT04809740?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04809740 being conducted?
This trial has 2 study locations across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04809740's enrollment target sits among peer trials
7,500 35th of 615 higher than 581 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
BfedBwell Optimization Pilot
RECRUITING · NA
-
Legal Evaluation for Greater Access to Cancer Care (LEGAL-CARE)
RECRUITING · NA
-
Optimizing the AYA Survivors' Coping and Emotional Needs Toolkit
RECRUITING · NA
-
Comprehensive Connected Cancer Care (C4): Intervention Evaluation
RECRUITING · NA
-
Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00439049 · 7,500 participants
Substance Abuse Pre-Treatment Screening Study
- NCT05199701 · 7,500 participants · NA
Prospective Case Collection Study for New Mammography Technologies
- NCT06112418 · 7,500 participants · NA
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
- NCT02915198 · 7,410 participants · Phase 4
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI